149 related articles for article (PubMed ID: 29733524)
1. Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.
Werner TL; Sachdev J; Swisher EM; Gutierrez M; Kittaneh M; Stein MN; Xiong H; Dunbar M; Sullivan D; Komarnitsky P; McKee M; Tan AR
Cancer Med; 2018 Jun; 7(6):2360-2369. PubMed ID: 29733524
[TBL] [Abstract][Full Text] [Related]
2. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
[TBL] [Abstract][Full Text] [Related]
3. Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
Anampa J; Chen A; Wright J; Patel M; Pellegrino C; Fehn K; Sparano JA; Andreopoulou E
Clin Breast Cancer; 2018 Feb; 18(1):e135-e142. PubMed ID: 28935542
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
Manzo J; Puhalla S; Pahuja S; Ding F; Lin Y; Appleman L; Tawbi H; Stoller R; Lee JJ; Diergaarde B; Kiesel BF; Yu J; Tan AR; Belani CP; Chew H; Garcia AA; Morgan RJ; Wahner Hendrickson AE; Visscher DW; Hurley RM; Kaufmann SH; Swisher EM; Oesterreich S; Katz T; Ji J; Zhang Y; Parchment RE; Chen A; Duan W; Giranda V; Shepherd SP; Ivy SP; Chu E; Beumer JH;
Cancer Chemother Pharmacol; 2022 May; 89(5):721-735. PubMed ID: 35435472
[TBL] [Abstract][Full Text] [Related]
5. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
LoRusso PM; Li J; Burger A; Heilbrun LK; Sausville EA; Boerner SA; Smith D; Pilat MJ; Zhang J; Tolaney SM; Cleary JM; Chen AP; Rubinstein L; Boerner JL; Bowditch A; Cai D; Bell T; Wolanski A; Marrero AM; Zhang Y; Ji J; Ferry-Galow K; Kinders RJ; Parchment RE; Shapiro GI
Clin Cancer Res; 2016 Jul; 22(13):3227-37. PubMed ID: 26842236
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
[TBL] [Abstract][Full Text] [Related]
7. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Rodler ET; Kurland BF; Griffin M; Gralow JR; Porter P; Yeh RF; Gadi VK; Guenthoer J; Beumer JH; Korde L; Strychor S; Kiesel BF; Linden HM; Thompson JA; Swisher E; Chai X; Shepherd S; Giranda V; Specht JM
Clin Cancer Res; 2016 Jun; 22(12):2855-64. PubMed ID: 26801247
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.
Jelinek MJ; Foster NR; Zoroufy AJ; Schwartz GK; Munster PN; Seiwert TY; de Souza JA; Vokes EE
Oral Oncol; 2021 Mar; 114():105171. PubMed ID: 33513474
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.
Nishikawa T; Matsumoto K; Tamura K; Yoshida H; Imai Y; Miyasaka A; Onoe T; Yamaguchi S; Shimizu C; Yonemori K; Shimoi T; Yunokawa M; Xiong H; Nuthalapati S; Hashiba H; Kiriyama T; Leahy T; Komarnitsky P; Fujiwara K
Cancer Sci; 2017 Sep; 108(9):1834-1842. PubMed ID: 28665051
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
Wesolowski R; Stover DG; Lustberg MB; Shoben A; Zhao M; Mrozek E; Layman RM; Macrae E; Duan W; Zhang J; Hall N; Wright CL; Gillespie S; Berger M; Chalmers JJ; Carey A; Balasubramanian P; Miller BL; Amaya P; Andreopoulou E; Sparano J; Shapiro CL; Villalona-Calero MA; Geyer S; Chen A; Grever MR; Knopp MV; Ramaswamy B
Oncologist; 2020 Aug; 25(8):e1158-e1169. PubMed ID: 32452601
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.
Su JM; Thompson P; Adesina A; Li XN; Kilburn L; Onar-Thomas A; Kocak M; Chyla B; McKeegan E; Warren KE; Goldman S; Pollack IF; Fouladi M; Chen A; Giranda V; Boyett J; Kun L; Blaney SM
Neuro Oncol; 2014 Dec; 16(12):1661-8. PubMed ID: 24908656
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
[TBL] [Abstract][Full Text] [Related]
13. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.
Wahner Hendrickson AE; Menefee ME; Hartmann LC; Long HJ; Northfelt DW; Reid JM; Boakye-Agyeman F; Kayode O; Flatten KS; Harrell MI; Swisher EM; Poirier GG; Satele D; Allred J; Lensing JL; Chen A; Ji J; Zang Y; Erlichman C; Haluska P; Kaufmann SH
Clin Cancer Res; 2018 Feb; 24(4):744-752. PubMed ID: 29138343
[No Abstract] [Full Text] [Related]
14. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
Villalona-Calero MA; Duan W; Zhao W; Shilo K; Schaaf LJ; Thurmond J; Westman JA; Marshall J; Xiaobai L; Ji J; Rose J; Lustberg M; Bekaii-Saab T; Chen A; Timmers C
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26848151
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline
Somlo G; Frankel PH; Arun BK; Ma CX; Garcia AA; Cigler T; Cream LV; Harvey HA; Sparano JA; Nanda R; Chew HK; Moynihan TJ; Vahdat LT; Goetz MP; Beumer JH; Hurria A; Mortimer J; Piekarz R; Sand S; Herzog J; Van Tongeren LR; Ferry-Galow KV; Chen AP; Ruel C; Newman EM; Gandara DR; Weitzel JN
Clin Cancer Res; 2017 Aug; 23(15):4066-4076. PubMed ID: 28356425
[No Abstract] [Full Text] [Related]
16. Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
Pothuri B; Brodsky AL; Sparano JA; Blank SV; Kim M; Hershman DL; Tiersten A; Kiesel BF; Beumer JH; Liebes L; Muggia F
Cancer Chemother Pharmacol; 2020 Apr; 85(4):741-751. PubMed ID: 32055930
[TBL] [Abstract][Full Text] [Related]
17. A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients.
Stodtmann S; Nuthalapati S; Eckert D; Kasichayanula S; Joshi R; Bach BA; Mensing S; Menon R; Xiong H
J Clin Pharmacol; 2021 Sep; 61(9):1195-1205. PubMed ID: 33894017
[TBL] [Abstract][Full Text] [Related]
18. Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.
Nuthalapati S; Stodtmann S; Shepherd SP; Ratajczak CK; Mensing S; Menon R; Xiong H
Cancer Chemother Pharmacol; 2019 Nov; 84(5):977-986. PubMed ID: 31468137
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).
Malhotra MK; Pahuja S; Kiesel BF; Appleman LJ; Ding F; Lin Y; Tawbi HA; Stoller RG; Lee JJ; Belani CP; Chen AP; Giranda VL; Shepherd SP; Emens LA; Ivy SP; Chu E; Beumer JH; Puhalla S
Breast Cancer Res Treat; 2023 Apr; 198(3):487-498. PubMed ID: 36853577
[TBL] [Abstract][Full Text] [Related]
20. Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study.
Steffensen KD; Adimi P; Jakobsen A
Int J Gynecol Cancer; 2017 Nov; 27(9):1842-1849. PubMed ID: 28763368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
